Page 2 - Michael Celano News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Board Continues Search for Permanent CEO Evaluation of Strategic Alternatives Ongoing BETHLEHEM, Pa., March 22, 2022 (GLOBE NEWSWIRE) --...

Board Continues Search for Permanent CEO

Share: BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia (FA) and other complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the CTI-1601 clinical program and that the company will not be closing a previously announced private placement financing. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who a...

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results May 10, 2021 16:05 ET | Source: Larimar Therapeutics Larimar Therapeutics Bala Cynwyd, UNITED STATES - Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a c...

Published: Mar 04, 2021 Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich's ataxia (FA) patients Cash and investments of $92.6 million as of December 31, 2020 BALA CYNWYD, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2020 operating and financial result...